# Novartis Investigates Tumor Reports Linked to Zolgensma Gene Therapy Nine pediatric tumor cases reported since 2019, with two potentially linked to treatment. - **Source:** [MedPage Today](https://www.medpagetoday.com) - **Published:** 2026-11-06 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/cca0dbe9-cb43-4fdb-9ef3-dd59c47ad23c ## Safety Signal Emerges Novartis has acknowledged nine reports of tumors in children treated with Zolgensma, a gene therapy for spinal muscular atrophy approved in 2019. While seven cases remain under investigation, the company confirmed that two instances show evidence of vector DNA integration into patient genomes, prompting increased scrutiny from global health authorities. ## Mechanism of Potential Risk Zolgensma utilizes an adeno-associated virus (AAV) vector to replace the defective SMN1 gene. The therapy's prescribing information already includes a theoretical risk of tumorigenicity due to potential vector DNA integration. This biological mechanism remains a primary focus for researchers evaluating whether the treatment directly caused these specific pediatric tumor developments. ## Scope of Patient Exposure More than 6,000 patients have received Zolgensma through clinical trials, managed access programs, and commercial distribution since its initial regulatory approval. Novartis maintains that it continuously evaluates new safety data. The company states it has timely notified health authorities regarding all reported cases to ensure ongoing patient safety and monitoring. ## Advocacy Groups Seek Clarity Patient advocacy organizations, including SMA Europe, have publicly acknowledged the reports and are currently awaiting further guidance from regulators. The Muscular Dystrophy Association in the U.S. is actively seeking additional information from Novartis, noting that limited data currently exists regarding the nature of the tumors and necessary long-term patient monitoring. ## Previous Clinical Case Reports Existing literature offers mixed findings on AAV-related risks. A 2023 report on a 16-month-old boy with a spinal cord neoplasm was deemed inconclusive. Conversely, a 2025 analysis of a pilocytic astrocytoma suggested the tumor was causally independent of the gene therapy, highlighting the complexity of diagnosing tumorigenesis in treated pediatric patients. ## Broader Industry Safety Context Concerns regarding AAV vector integration extend beyond Zolgensma. Researchers recently identified vector integration in a brain tumor of a five-year-old boy treated with a different AAV gene therapy for Hurler syndrome. This case, documented in the New England Journal of Medicine, underscores the industry-wide challenge of assessing long-term genomic safety. ## History of Regulatory Scrutiny This is not the first controversy surrounding the therapy. Shortly after the 2019 approval, the FDA criticized the Novartis AveXis unit for data manipulation involving animal product-testing results. These past regulatory issues have heightened the sensitivity of families and physicians regarding the transparency of current safety data and reporting protocols. ## Future Monitoring and Assessment Regulatory authorities are currently assessing the available evidence to determine if further safety measures are required. As Novartis continues to monitor treated individuals, the medical community awaits more definitive data on the timing and nature of these events, which will ultimately dictate future clinical guidelines for patients receiving gene therapies. ## Sources covering this story - [Source — Novartis Faces Scrutiny Over Tumor Reports in Zolgensma Patients](https://www.medpagetoday.com/neurology/generalneurology/123769) - [STAT — Novartis Reports Potential Tumor Risks Linked to Zolgensma Gene Therapy](https://www.statnews.com/pharmalot/2026/11/05/novartis-sma-zolgensma-tumor-case-reports/?utm_campaign=rss) - [STAT — Amgen's Repatha Linked to Reduced Heart Attack Risk](https://www.statnews.com/2026/11/06/biotech-news-amgen-repatha-linked-to-fewer-heart-attacks/?utm_campaign=rss) --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._